Assert-IQ vs Eko Low Ejection Fraction Tool (ELEFT)
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if your clinical objective is long-term, continuous monitoring for comprehensive arrhythmia detection in patients with suspected heart rhythm disorders. This insertable cardiac monitor is ideal for identifying infrequent or asymptomatic arrhythmias over several years, providing detailed data for diagnosis and ongoing management.
View Assert-IQ →Choose Eko Low Ejection Fraction Tool (ELEFT) if…
Choose Eko Low Ejection Fraction Tool (ELEFT) if you need a rapid, non-invasive screening tool to aid in the early detection of low ejection fraction during routine physical examinations. This AI-powered solution, integrated with digital stethoscopes, is best suited for quickly identifying patients at risk for heart failure, prompting timely referrals for more definitive diagnostic testing.
View Eko Low Ejection Fraction Tool (ELEFT) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Assert-IQ | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Deployment | Subcutaneously implanted device with mobile app connectivity | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Low Ejection Fraction Tool (ELEFT)Tool B (ELEFT) offers superior usability due to its non-invasive nature, integrating with a standard digital stethoscope for rapid results during routine physical exams. In contrast, Tool A (Assert-IQ) requires a minimally invasive surgical procedure for insertion, which inherently presents a higher barrier to immediate use for both patients and clinicians.
Clinical Value
Assert-IQTool A (Assert-IQ) provides long-term, continuous cardiac monitoring for up to six years, offering comprehensive and sustained data for diagnosing and managing complex arrhythmias. While Tool B (ELEFT) is valuable for early, non-invasive screening of low ejection fraction, Tool A's ability to capture episodic events over an extended period offers a deeper and more persistent clinical insight for its specific application.
Pricing & Value
TieBoth tools utilize an enterprise pricing model that requires direct contact with their respective sales teams for specific details, and neither offers a free trial. The lack of transparent, publicly available pricing information for either product makes a direct comparison of their pricing and value impossible.
Enterprise Readiness
Assert-IQBoth tools are FDA-cleared and HIPAA compliant, targeting enterprise healthcare systems. However, Abbott Medical, the company behind Tool A, is a global, well-established medical device leader with extensive experience in large-scale deployments and robust enterprise support infrastructure. Tool A's hybrid deployment also offers potential flexibility for diverse IT environments, which can be critical for large health systems.
Innovation
Eko Low Ejection Fraction Tool (ELEFT)Tool B (ELEFT) demonstrates greater innovation by integrating an AI algorithm into a common, non-invasive diagnostic tool like a digital stethoscope for rapid, early detection of low ejection fraction. This approach makes advanced cardiac screening more accessible and efficient within routine physical exams. Tool A, while offering advanced features for an Insertable Cardiac Monitor, builds upon an existing device category.
Support & Docs
Assert-IQWhile specific details on support and documentation are not provided for either tool in the structured facts, Abbott Medical (Tool A) is a global, long-standing leader in the medical device industry. This extensive history and scale strongly suggest a more mature, comprehensive, and widely available support system and documentation compared to a relatively newer company like Eko Health (Tool B).
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Product Name | Assert-IQ | Eko Low Ejection Fraction Tool (ELEFT) |
| Company | Abbott Medical | Eko Health |
| Primary Use Case | Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | FDA-cleared AI algorithm that integrates with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams. |
| Core Detection Focus | Advanced arrhythmia detection | Low ejection fraction detection |
| Required Hardware/Integration | Insertable Cardiac Monitor (ICM) | Eko digital stethoscopes |
| Target Market | Large health systems, hospitals, cardiology clinics | Enterprise (implied by 'enterprise solution') |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and Eko Low Ejection Fraction Tool (ELEFT).
Frequently Asked Questions
More Comparisons
More matchups featuring Assert-IQ or Eko Low Ejection Fraction Tool (ELEFT)
Backers
Who funded each tool's parent company.